Glioblastoma Multiforme (GBM) research hub
3 indexed studies · 3 currently recruiting
- recruitingPHASE1, PHASE2
5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
This study is testing two new drugs, avutometinib and defactinib, alone and with temozolomide, for people with aggressive brain tumours like glioblastoma. It aims to see if they are safe and can shrink tumours, particularly in patients with specific genetic changes.
United Kingdom - recruitingPHASE1
5G-EMERALD: Amivantamab in Malignant Brain Tumours
This study, called 5G-EMERALD, is testing a new drug called amivantamab for people with certain types of aggressive brain tumours. It aims to see if the drug is safe and if it helps shrink tumours, especially in patients whose tumours have a specific genetic feature.
United Kingdom - recruitingPHASE2
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
This study is looking at new drug combinations to treat certain types of brain tumours in children and young adults. It aims to see if combining ribociclib with either everolimus or temozolomide can help patients live longer and improve their health.
United States · Australia · Canada